Ruane Cunniff Cuts Valeant Pharmaceuticals Stake Almost in Half

  • Firm’s Sequoia Fund slid 27% as drugmaker’s shares plunged
  • Valeant falls further today as CEO cuts 2016 earnings forecast

Valeant Falls After Cutting Profit Forecast

Ruane, Cunniff & Goldfarb, once the largest shareholder in Valeant Pharmaceuticals International Inc., cut its stake in the troubled drug maker almost in half, according to a regulatory filing Tuesday.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.